Aligos Therapeutics (ALGS) Operating Expenses (2019 - 2026)

Aligos Therapeutics has reported Operating Expenses for 8 years, with the latest figure at $29.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 52.19% year-over-year to $29.8 million; the trailing twelve-month figure through Mar 2026 stood at $100.4 million (up 12.0% YoY), and the FY2025 full-year result was $90.2 million, down 3.15% from the prior year.
• Operating Expenses for Q1 2026 stood at $29.8 million, up from $22.0 million in the prior quarter.
• The five-year high for Operating Expenses was $38.1 million in Q1 2022, with the low at $19.5 million in Q2 2025.
• Historically, Operating Expenses has averaged $25.2 million across 5 years, with a median of $24.1 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Expenses plunged 33.38% — and 2026, when it jumped 52.19%.
• Aligos Therapeutics' Operating Expenses stood at $26.2 million in 2022, then gained by 9.38% to $28.7 million in 2023, then declined by 26.1% to $21.2 million in 2024, then rose by 3.73% to $22.0 million in 2025, then surged by 35.37% to $29.8 million in 2026.
• The last three Operating Expenses figures came in at $29.8 million (Q1 2026), $22.0 million (Q4 2025), and $29.1 million (Q3 2025), per Business Quant data.